Exact Sciences Corp (NASDAQ: EXAS) on Friday, soared 0.04% from the previous trading day, before settling in for the closing price of $56.03. Within the past 52 weeks, EXAS’s price has moved between $40.62 and $79.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 31.64% over the past five years. The company achieved an average annual earnings per share of -2.48%. With a float of $182.43 million, this company’s outstanding shares have now reached $185.05 million.
Let’s look at the performance matrix of the company that is accounted for 6600 employees. In terms of profitability, gross margin is 72.1%, operating margin of -8.76%, and the pretax margin is -7.82%.
Exact Sciences Corp (EXAS) Insider and Institutional Ownership
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Exact Sciences Corp is 1.43%, while institutional ownership is 99.34%. The most recent insider transaction that took place on Nov 13 ’24, was worth 1,001,325. In this transaction President and CEO of this company bought 19,500 shares at a rate of $51.35, taking the stock ownership to the 1,074,191 shares. Before that another transaction happened on Oct 08 ’24, when Company’s EVP, GM, Precision Oncology sold 929 for $70.00, making the entire transaction worth $65,030. This insider now owns 12,758 shares in total.
Exact Sciences Corp (EXAS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -2.48% per share during the next fiscal year.
Exact Sciences Corp (NASDAQ: EXAS) Trading Performance Indicators
Exact Sciences Corp (EXAS) is currently performing well based on its current performance indicators. A quick ratio of 1.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.85. Likewise, its price to free cash flow for the trailing twelve months is 105.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.17, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Exact Sciences Corp (EXAS)
Exact Sciences Corp (NASDAQ: EXAS) saw its 5-day average volume 1.44 million, a negative change from its year-to-date volume of 2.42 million. As of the previous 9 days, the stock’s Stochastic %D was 75.98%. Additionally, its Average True Range was 2.47.
During the past 100 days, Exact Sciences Corp’s (EXAS) raw stochastic average was set at 32.37%, which indicates a significant decrease from 56.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.24% in the past 14 days, which was lower than the 60.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.41, while its 200-day Moving Average is $56.92. Nevertheless, the first resistance level for the watch stands at $57.06 in the near term. At $58.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $58.93. If the price goes on to break the first support level at $55.20, it is likely to go to the next support level at $54.35. The third support level lies at $53.34 if the price breaches the second support level.
Exact Sciences Corp (NASDAQ: EXAS) Key Stats
Market capitalization of the company is 10.37 billion based on 185,076K outstanding shares. Right now, sales total 2,500 M and income totals -204,150 K. The company made 708,660 K in profit during its latest quarter, and -38,240 K in sales during its previous quarter.
